Novartis AG (NVS)
97.50
+0.37
(+0.38%)
USD |
NYSE |
May 01, 16:00
97.65
+0.15
(+0.15%)
Pre-Market: 08:58
Novartis Cash from Operations (Quarterly): 2.265B for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 2.265B |
| December 31, 2023 | 2.547B |
| September 30, 2023 | 5.378B |
| June 30, 2023 | 3.576B |
| March 31, 2023 | 2.957B |
| December 31, 2022 | 4.111B |
| September 30, 2022 | 4.721B |
| June 30, 2022 | 3.755B |
| March 31, 2022 | 1.649B |
| December 31, 2021 | 3.884B |
| September 30, 2021 | 4.925B |
| June 30, 2021 | 4.132B |
| March 31, 2021 | 2.13B |
| December 31, 2020 | 4.005B |
| September 30, 2020 | 3.156B |
| June 30, 2020 | 3.961B |
| March 31, 2020 | 2.528B |
| December 31, 2019 | 3.54B |
| September 30, 2019 | 4.562B |
| June 30, 2019 | 3.111B |
| March 31, 2019 | 2.412B |
| December 31, 2018 | 3.766B |
| September 30, 2018 | 4.05B |
| June 30, 2018 | 3.942B |
| March 31, 2018 | 2.514B |
| Date | Value |
|---|---|
| December 31, 2017 | 3.408B |
| September 30, 2017 | 3.586B |
| June 30, 2017 | 3.582B |
| March 31, 2017 | 2.045B |
| December 31, 2016 | 3.591B |
| September 30, 2016 | 3.231B |
| June 30, 2016 | 3.111B |
| March 31, 2016 | 1.542B |
| December 31, 2015 | 4.157B |
| September 30, 2015 | 3.126B |
| June 30, 2015 | 2.91B |
| March 31, 2015 | 1.704B |
| December 31, 2014 | 5.205B |
| September 30, 2014 | 4.011B |
| June 30, 2014 | 3.34B |
| March 31, 2014 | 1.341B |
| December 31, 2013 | 4.45B |
| September 30, 2013 | 4.379B |
| June 30, 2013 | 2.517B |
| March 31, 2013 | 1.828B |
| December 31, 2012 | 4.627B |
| September 30, 2012 | 4.066B |
| June 30, 2012 | 2.985B |
| March 31, 2012 | 2.516B |
| December 31, 2011 | 4.722B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
1.649B
Minimum
Mar 2022
5.378B
Maximum
Sep 2023
3.545B
Average
3.666B
Median
Cash from Operations (Quarterly) Benchmarks
| Sandoz Group AG | -- |
| Amgen Inc | 538.00M |
| AstraZeneca PLC | 2.486B |
| Incyte Corp | 218.81M |
| MorphoSys AG | -- |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -899.00M |
| Cash from Financing (Quarterly) | -5.164B |
| Free Cash Flow | 10.25B |
| Free Cash Flow Per Share (Quarterly) | 0.5394 |
| Free Cash Flow to Equity (Quarterly) | 99.00M |
| Free Cash Flow to Firm (Quarterly) | 1.294B |
| Free Cash Flow Yield | 5.06% |